Current Report Filing (8-k)
02 Junho 2023 - 9:40AM
Edgar (US Regulatory)
0001125345FALSE00011253452022-05-192022-05-19
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 31, 2023
MACROGENICS, INC.
(Exact Name of Registrant as Specified in Charter)
| | | | | | | | | | | | | | | | | |
| Delaware | | 001-36112 | | 06-1591613 |
(State or Other Jurisdiction of Incorporation) | | (Commission
File Number) | | (IRS Employer Identification No.) |
| | | | | |
| 9704 Medical Center Drive | | | | |
| Rockville, | Maryland | | 20850 |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant's telephone number, including area code: (301) 251-5172
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Securities registered pursuant to Section 12(b) of the Act: | | | | | | | | |
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.01 per share | MGNX | Nasdaq Global Select Market |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| | | | | |
| Item 5.07 | Submission of Matters to a Vote of Security Holders. |
MacroGenics, Inc. (the "Company") held its 2023 Annual Meeting of Stockholders on May 31, 2023. A total of 52,689,364 shares of the Company's common stock were present or represented by proxy at the meeting, which represented approximately 85% of the Company's 61,838,565 shares of common stock that were outstanding and entitled to vote at the meeting as of the record date of April 3, 2023. Stockholders considered the four proposals outlined below, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 17, 2023 (the "Proxy Statement").
Proposal 1. The election of three nominees to serve as Class I directors, each for a term of three years. All director nominees were elected. The voting results were as follows:
| | | | | | | | | | | | | | | | | | | | |
| Nominees | | For | | Withheld | | Broker Non-Votes |
| Scott Koenig, M.D., Ph.D. | | 43,810,609 | | 5,264,596 | | 3,614,159 |
| Federica O'Brien | | 43,467,303 | | 5,607,902 | | 3,614,159 |
| Jay Siegel, M.D. | | 41,788,095 | | 7,287,110 | | 3,614,159 |
Proposal 2. The ratification of the appointment by the Audit Committee of the Board of Directors of the Company of Ernst & Young LLP as the Company's independent registered public accounting firm for fiscal year 2023. Proposal 2 was approved. The voting results were as follows:
| | | | | | | | | | | | | | | | | | | | |
| For | | Against | | Abstain | | Broker Non-Votes |
| 47,636,172 | | 5,024,405 | | 28,787 | | — |
Proposal 3. To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's Proxy Statement. Stockholders approved the compensation of the Company's named executive officers. The voting results were as follows:
| | | | | | | | | | | | | | | | | | | | |
| For | | Against | | Abstain | | Broker Non-Votes |
| 43,633,412 | | 5,433,960 | | 7,833 | | 3,614,159 |
Proposal 4. To approve the MacroGenics, Inc. 2023 Equity Incentive Plan (the "2023 Plan"). Stockholders approved the 2023 Plan. The voting results were as follows:
| | | | | | | | | | | | | | | | | | | | |
| For | | Against | | Abstain | | Broker Non-Votes |
| 32,287,594 | | 16,781,647 | | 5,964 | | 3,614,159 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | | |
| MACROGENICS, INC. |
| Date: June 2, 2023 | By: Name: Title: | /s/ James Karrels James Karrels Senior Vice President, Chief Financial Officer and Secretary |
MacroGenics (NASDAQ:MGNX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
MacroGenics (NASDAQ:MGNX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
